QIAGEN OmicSoft and Biomedical Knowledge Base
Checkpoint inhibitor and immuno-oncology investigation leveraging curated high-quality public omics data
24 views
While there is great interest in the scientific community to investigate drug targets and biomarkers from public immune-oncology data, such investigation is hindered by the difficulty in finding and combining related datasets to perform large-scale meta-analyses. This webinar will focus on how high-quality curated genomic repositories such as QIAGEN OmicSoft Lands immediately allows in-depth investigations across diverse data sources (GEO, CPTAC, TCGA, GTEx and more) to discover and validate candidate checkpoint inhibitor drug targets and biomarkers.
You will learn how to do the following in the graphical user interface and through APIs:
- Easily identify relevant samples using extensive manually curated clinical metadata
- Visualize and identify checkpoint inhibition biology related drug target and biomarkers expression patterns using expression data (RNA-seq, scRNA-seq, proteomics etc.)
- Reveal how the expression of a group of biomarkers (or genes/proteins of interest) correlates in normal and disease tissue
Related videos
QIAGEN OmicSoft and Biomedical Knowledge Base
Knowledge graphs and more: Analytics-driven drug discovery using advanced biomedical...
High-quality biomedical relationships knowledge is the cornerstone of modern...
QIAGEN OmicSoft and Biomedical Knowledge Base
QIAGEN OmicSoft trainings- 3 part series - Oct 20 (part 1)
In three separate 60-minute trainings, attendees will learn how to use basic...
QIAGEN OmicSoft and Biomedical Knowledge Base
Expression data analysis using QIAGEN Omicsoft Studio - Sep 28 2021
In this training, users will learn how to generate downstream outputs such...